AVALIAÇÃO DO POLIMORFISMO 4G/5G DO PAI-1 EM PACIENTES COM ACIDENTE VASCULAR ENCEFÁLICO ISQUÊMICO E SEUS SUBTIPOS
Palavras-chave:
Polimorfismo PAI-1, Acidente vascular encefálico isquêmico - subtipos.Resumo
: O PAI-1 (Inibidor do Ativador do Plasminogênio-1) é uma glicoproteína pertencente à família das serpinas, que é o principal inibidor dos ativadores do plasminogênio do tipo tecidual (tPA) e do tipo uroquinase (uPA). O aumento dos níveis de PAI-1 afeta o sistema fibrinolítico e influencia o coágulo de fibrina e pode estar associado ao desenvolvimento de doenças tromboembólicas, como infarto do miocárdio e acidente vascular encefálico, no entanto, sua ação neste último ainda é controversa. O gene PAI-1 possui vários locus polimórficos, incluindo uma inserção / deleção 4G / 5G a 675 pb a partir do início do promotor. Tem sido relatado que indivíduos com genótipo 4G / 4G têm níveis plasmáticos de PAI-1 significativamente mais elevados (cerca de 25%) do que indivíduos com outros genótipos (4G / 5G e 5G / 5G). Devido a poucos estudos correlacionando o polimorfismo do gene PAI-1 com a susceptibilidade e a etiologia do AVE, foi comparado o genótipo da distribuição do polimorfismo 4G / 5G nos diferentes subtipos de AVE. Uma coleta de sangue venoso de pacientes admitidos para acompanhamento pós-AVE no Serviço de Neurologia da Santa Casa de Belo Horizonte (Total n = 144; 43 aterotrombóticos, 39 cardioembólicos, 40 lacunares e 22 criptogênicos) e a coleta de sangue venoso dos controles (n = 112) foram realizadas nas especialidades médicas da Santa Casa. O grupo controle e os pacientes foram ajustados por idade, sexo, hipertensão, diabetes e tabagismo. A análise do polimorfismo foi realizada pela reação em cadeia da polimerase (PCR). A análise estatística foi realizada para comparação entre os grupos. Diferença significativa entre os grupos foi considerada para p<0,05. Correlacionamos o polimorfismo entre pacientes / controles e com suscetibilidade a diferentes etiologias do AVE e não foram encontradas diferenças significativas em ambos (p>0,05). Esses resultados sugerem que o polimorfismo PAI-1 não está relacionado ao risco de AVE, bem como a suscetibilidade a qualquer um dos subtipos. Estes resultados são suportados por outros estudos.
Downloads
Referências
ADAMS, H. P. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke; a journal of cerebral circulation, [s. l.], v. 24, n. 1, p. 35–41, 1993. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/7678184>
ADAMSKI, M. G. et al. A-G-4G haplotype of PAI-1 gene polymorphisms -844 G/A, HindIII G/C, and -675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease. Acta neurologica Scandinavica, [s. l.], v. 120, n. 2, p. 94–100, 2009. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/19154538>. Acesso em: 29 nov. 2011.
ALBERS, Gregory W. et al. Diretrizes Clínicas Acidente Vascular Cerebral IsquêmicoScreening. [s.l: s.n.].
ATTIA, John et al. The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, [s. l.], v. 16, n. 4, p. 173–9, 2007. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/17689414>. Acesso em: 4 jan. 2012.
BABU, M. Sai et al. Association of genetic variants of fibrinolytic system with stroke and stroke subtypes. Gene, [s. l.], v. 495, n. 1, p. 76–80, 2012. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/22240314>. Acesso em: 2 jan. 2013.
BROUNS, R.; DE DEYN, P. P. The complexity of neurobiological processes in acute ischemic stroke. Clinical neurology and neurosurgery, [s. l.], v. 111, n. 6, p. 483–95, 2009. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/19446389>. Acesso em: 25 jul. 2011.
CASAS, Juan P. et al. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Archives of neurology, [s. l.], v. 61, n. 11, p. 1652–61, 2004. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/18511872>
CAVALCANTE, Tahissa Frota et al. Demographic factors and risk indicators of stroke: comparison between inhabitants of Fortaleza municipal district and the national profile. Revista latino-americana de enfermagem, [s. l.], v. 18, n. 4, p. 703–8, 2010. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/20922316>
COLLEN, D. Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling. Hematology: American Society of Hematology, Education Program, [s. l.], p. 1–9, 2001. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/11722975>
CURIONI, Cintia et al. The decline in mortality from circulatory diseases in Brazil. Revista panamericana de salud pública = Pan American journal of public health, [s. l.], v. 25, n. 1, p. 9–15, 2009. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/19341518>
DE PAULA SABINO, Adriano et al. Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and PAI-1 plasma levels in young patients with ischemic stroke. Molecular Biology Reports, [s. l.], v. 38, n. 8, p. 5355–60, 2011. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/21373825>. Acesso em: 1 fev. 2012.
DING, Jingzhong et al. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. American heart journal, [s. l.], v. 152, n. 6, p. 1109–15, 2006. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/17161063>. Acesso em: 24 ago. 2011.
DOYLE, Kristian P.; SIMON, Roger P.; STENZEL-POORE, Mary P. Neuropharmacology – Special Issue on Cerebral Ischemia Mechanisms of Ischemic Brain Damage – Review Article. Molecular Microbiology, [s. l.], v. 55, n. 3, p. 310–318, 2009.
EITZMAN, DT et al. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. Journal of Clinical Investigation, [s. l.], v. 95, n. 5, p. 2416, 1995. Disponível em: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC295874/>. Acesso em: 1 fev. 2012.
ERIKSSON, P. E. R. et al. Allele-specffic increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proceedings of the National Academy of Sciences of the United States of America, [s. l.], v. 92, p. 1851–1855, 1995.
HENRY, M. et al. Metabolic Determinants Are Much More Important Than Genetic Polymorphisms in Determining the PAI-1 Activity and Antigen Plasma Concentrations : A Family Study With Part of the Stanislas Cohort. Arteriosclerosis, Thrombosis, and Vascular Biology, [s. l.], v. 18, n. 1, p. 84–91, 1998. Disponível em: <http://atvb.ahajournals.org/cgi/doi/10.1161/01.ATV.18.1.84>. Acesso em: 1 fev. 2012.
HOEKSTRA, Tiny et al. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke; a journal of cerebral circulation, [s. l.], v. 34, n. 12, p. 2822–8, 2003. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/14605330>. Acesso em: 1 fev. 2012.
HULTMAN, Karin et al. Allele-specific transcription of the PAI-1 gene in human astrocytes. Thrombosis and haemostasis, [s. l.], v. 104, n. 5, p. 998–1008, 2010. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/20806116>. Acesso em: 24 jan. 2012.
JOHANSSON, Lars et al. Tissue Plasminogen Activator , Plasminogen Activator Development of a First Stroke. Stroke, [s. l.], 2000.
JOOD, Katarina et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke; a journal of cerebral circulation, [s. l.], v. 36, n. 10, p. 2077–81, 2005. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/16179568>. Acesso em: 21 dez. 2011.
KATO, H.; KOGURE, K. Biochemical and molecular characteristics of the brain with developing cerebral infarction. Cellular and molecular neurobiology, [s. l.], v. 19, n. 1, p. 93–108, 1999. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/10079969>
LUPU, F. et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arteriosclerosis, Thrombosis, and Vascular Biology, [s. l.], v. 13, n. 7, p. 1090–1100, 1993. Disponível em: <http://atvb.ahajournals.org/cgi/doi/10.1161/01.ATV.13.7.1090>. Acesso em: 3 fev. 2012.
LUTTUN, A. Lack of Plasminogen Activator Inhibitor-1 Promotes Growth and Abnormal Matrix Remodeling of Advanced Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, [s. l.], v. 22, n. 3, p. 499–505, 2002. Disponível em: <http://atvb.ahajournals.org/cgi/doi/10.1161/hq0302.104529>. Acesso em: 24 jan. 2012.
MARKUS, Hugh. Stroke: causes and clinical features. Medicine, [s. l.], v. 40, n. 9, p. 484–489, 2012. Disponível em: <http://linkinghub.elsevier.com/retrieve/pii/S1357303912001326>. Acesso em: 13 nov. 2012.
MOHR, J. P. et al. Etiology of Stroke Diagnosis of Ischemic Stroke Mechanism Embolism to the Brain of Cardiac or Aortic Origin. Therapy, [s. l.], p. 1501–1506, 1997.
MONTAGU, Alexandra; RECKLESS, Ian P.; BUCHAN, Alastair M. Stroke: management and prevention. Medicine, [s. l.], v. 40, n. 9, p. 490–499, 2012. Disponível em: <http://linkinghub.elsevier.com/retrieve/pii/S135730391200134X>. Acesso em: 2 jan. 2013.
MONTANER, Joan et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke; a journal of cerebral circulation, [s. l.], v. 39, n. 8, p. 2280–7, 2008. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/18535284>. Acesso em: 28 jun. 2011.
OH, CK et al. PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochemical and biophysical …, [s. l.], v. 294, p. 1155–1160, 2002. Disponível em: <http://www.sciencedirect.com/science/article/pii/S0006291X02005776>. Acesso em: 4 jan. 2013.
PETROVIC, D. et al. Prothrombotic gene polymorphisms and atherothrombotic cerebral infarction. Acta neurologica Scandinavica, [s. l.], v. 108, n. 2, p. 109–13, 2003. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/12859287>
PIERI, Alexandre et al. Prevalence of cardiovascular risk factors among elderly Brazilians over eighty with ischemic stroke. Arquivos de neuro-psiquiatria, [s. l.], v. 66, n. 3A, p. 454–7, 2008. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/18813698>
RAO, Rohit et al. Ischaemic stroke subtypes and their genetic basis: a comprehensive meta-analysis of small and large vessel stroke. European neurology, [s. l.], v. 61, n. 2, p. 76–86, 2009. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/19039225>. Acesso em: 23 ago. 2011.
ROGER, Véronique L. et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation, [s. l.], v. 123, n. 4, p. e18–e209, 2011. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/21160056>. Acesso em: 13 jun. 2011.
ROPPER, A. H. et al. Adams and Victor’s principles of neurology. [s.l.] : McGraw-Hill Professional, 2005. Disponível em: <http://journals.lww.com/neurosurgery/Abstract/1998/02000/Principles_of_Neurology,_6th_Edition.148.aspx>. Acesso em: 18 jan. 2012.
ROSSIGNOL, P. Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques. … of Thrombosis and …, [s. l.], 2006. Disponível em: <http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2005.01765.x/full>. Acesso em: 2 jan. 2013.
SAENGER, Amy K.; CHRISTENSON, Robert H. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clinical chemistry, [s. l.], v. 56, n. 1, p. 21–33, 2010. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/19926776>. Acesso em: 16 mar. 2011.
SAIDI, Sarra et al. Association of PAI-1 4G/5G and -844G/A gene polymorphism and changes in PAI-1/tPA levels in stroke: a case-control study. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, [s. l.], v. 16, n. 4, p. 153–9, 2007. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/17689411>. Acesso em: 24 jan. 2012.
SAPOSNIK, Gustavo et al. IScore: A Risk Score to Predict Death Early After Hospitalization for an Acute Ischemic Stroke. Circulation, [s. l.], v. 123, n. 7, p. 739–749, 2011. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/21300951>. Acesso em: 15 mar. 2011.
SU, Shaoyong et al. Plasminogen activator inhibitor-1 gene: selection of tagging single nucleotide polymorphisms and association with coronary heart disease. Arteriosclerosis, thrombosis, and vascular biology, [s. l.], v. 26, n. 4, p. 948–54, 2006. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/16424345>. Acesso em: 24 jan. 2012.
VAN GOOR, M. L. et al. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study. Thromb Haemost, [s. l.], v. 93, n. 1, p. 92–96, 2005. Disponível em: <http://www.schattauer.de/en/magazine/subject-areas/journals-a-z/thrombosis-and-haemostasis/contents/archive/issue/759/manuscript/3983.html>. Acesso em: 3 fev. 2012.
WANG, Xiaoying et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke; a journal of cerebral circulation, [s. l.], v. 35, n. 11 Suppl 1, p. 2726–30, 2004. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/15459442>. Acesso em: 15 dez. 2012.
WARDEN, Donald R.; REFSUM, Helga. Detection of single-nucleotide polymorphisms by PCR with universal energy transfer-labeled primers: application to folate- and cobalamin-related genes. Clinical chemistry, [s. l.], v. 51, n. 9, p. 1713–6, 2005. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/16037414>. Acesso em: 10 out. 2011.
YANG, Quanhe et al. Improving the prediction of complex diseases by testing for
multiple disease-susceptibility genes. American journal of human genetics, [s. l.], v. 72, n. 3, p. 636–49, 2003. Disponível em: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1180239&tool=pmcentrez&rendertype=abstract>
YEH, Poh-shiow et al. Prognosis of young ischemic stroke in Taiwan : impact of prothrombotic genetic polymorphisms. Genetic Analysis, [s. l.], p. 583–589, 2004.
